We describe a new multianalyte immunoassay principle and apply it to the simultaneous immunoassay of lutropin, follitropin, choriogonadotropin, and prolactin in serum. The method is based on the coating of distinct areas of polystyrene with analyte-specific antibodies. These antibodies react with the analyte and immobilize it in a specific area while another biotinylated antibody also reacts with the analyte to form a sandwich. After addition of streptavidin labeled with the fluorescent europium chelate of 4,7-bis(chlorosulfophenyl)-1, 10-phenanthroline-2,9-dicarboxylic acid, fluorescent areas are formed, the intensity of which is related to the amount of each analyte present in the sample. The fluorescent areas are quantified on the dry solid phase with laser-excited timeresolved fluorometric measurements. The assays developed are highly sensitive, precise, and accurate. We believe that this system shows potential for multianalyte immunoassay of diverse groups of compounds in disciplines such as endocrinology, infectious disease, hematology, and oncology. A practical, true multianalyte immunoassay system recently became available commercially (17) . In this system, nitrocellulose is the solid-phase matrix that contains distinct regions coated with various antigens of infectious agents. When serum is added, any antigenspecific antibodies present bind to the specific antigen regions. This binding step is followed by addition of
between the disintegration produced by 57Co and 125! tracers. Similarly, simultaneous assays for LI! and FSH (5), for TSH and free thyroxin (6, 7), and for TSH and total thyroxin (8) also exist, based on 57Co and 125J tracers.
Recently, dual-label immunoassays involving timeresolved fluorometry
and either europium-terbium (9, 10) or europium-samarium These label combinations take advantage of the narrow fluorescence emission bands of the lanthanide chelates and the lack of overlap between their emission spectra (13). Thus, two lanthanides can be quantified in the presence of each other.
True multianalyte immunoassay, however, is not feasible with either radionuclides or lanthanides as labels because there are no known combinations of more than two or three radionuclides or lanthanides that can be quantified individually in a mixture. Moreover, because of the different detectabilities of these labels, the detection limits of the analytes of interest are different and in many instances are compromised because of the suboptimal label used (9).
Ekins et al. (14) (15) (16) have repeatedly proposed interesting ideas for devising novel multianalyte immunoassays. Their method is based on the use of a very small amount of antibody molecules immobilized on a microspot on a solid phase. These antibodies will bind a tiny fraction of the analyte of interest and the fractional occupancy of antibody binding sites will be proportional to the analyte concentration.
One version of this principle also uses a labeled detection antibody in a manner similar to the conventional noncompetitive immunoassay. This principle can be used for multianalyte immunoassay if the binding antibodies are coated to defined areas of the solid phase, which are then scanned for signal quantification with a proper instrument. Practical examples of this assay principle have been published (14-16).
A practical, true multianalyte immunoassay system recently became available commercially (17) . In this system, nitrocellulose is the solid-phase matrix that contains distinct regions coated with various antigens of infectious agents. When serum is added, any antigenspecific antibodies present bind to the specific antigen regions. This binding step is followed by addition of 
Materials and Methods

Instrumentation
For solid-phase time-resolved fluorometric measurements, we used the CyberFluor 615" Immunoanalyzer (CyberFluor Inc., Toronto, Canada).
Materials
The Preparation of the solid-phase antibodies. The coating solutions of the different antibodies were prepared by diluting separately the monoclonal antibodies to the intact LH, to the beta subunit of FSH, to the beta subunit of hCG, and to PRL in the coating buffer to a final concentration of 5 mg/L. We then added 100 /1L of these solutions per well in white microtiter strips (Dynatech Labs., Alexandria, VA 22314) and allowed the antibody to adsorb to the wells at room temperature overnight. The wells were then washed twice with the wash solution, and 200 iL of the blocking buffer was (8) added per well. After a 1-h incubation, the wells were washed briefly with isotonic saline, blotted dry, and lyophilized.
The wells coated with the specific antibody for each analyte were then marked at 2.5 mm from the outer surface of the bottom of the wells and were cut at that position with a blade. The resulting well bottoms were mounted in a fixed order onto a plastic stick, with chloroform or epoxy glue as the fixative. The configuration is shown in Figure 1 ; two well bottoms were fixed on one side of the stick and two were fixed on the opposite side. The distance between the two adjacent well bottoms was carefully chosen so that they could fit into holes of a plastic microtiter-well strip holder and their fluorescence be read with the 615 Immunoanalyzer. Sticks with the affixed well bottoms were stored dry under reduced pressure until use. Before use, they were incubated for 1 h in the blocking solution to saturate any uncoated surfaces of the sticks.
Assay procedure. Pipet 150 pL of standards or samples into 12 x 75 mm glass tubes (in duplicate or triplicate), and add 1 mL of biotinylated antibodies working mixture solution and one stick to each tube. out of the tubes, and blot them briefly on paper towels. Assemble the sticks in the appropriate order, place them into 96-well strip holders, dry them for 10 mm at 50#{176}C, and measure the fluorescence on the dried surface of the two discs with the 615 Immunoanalyzer. Then, turn the sticks around and read the fluorescence of the other two discs. Each row of the printout corresponds to one analyte. The fluorescence readings can be interpreted manually or by using the built-in computer of the Immunoanalyzer. Precision. To evaluate the precision of the developed assays, we assayed pooled human sera with three different concentrations of each of the analytes.
Results
Calibration
Withinrun precision was determined by analyzing eight replicates of each sample in the same run ( Table 1 the estimated endogenous concentration of each analyte, was close to 100% for each analyte (Table 2) .
Specificity.
Each of the four assays was tested for cross-reactivity with the other three analytes.
Standards diluent buffer was supplemented with various amounts of each analyte, and the equivalent concentration of each hormone was then calculated from the corresponding dose-response curve.
We found that the cross-reactivity of FSH in the LII assay was 5.5% for FSH s500 mt.units/L, whereas the cross-reactivity of LH in the FSH assay was 0.2% for LH 500 hit. unitafL. PRL and hCG did not interfere in the 
Discussion
There is increased interest for the simultaneous assay of more than two analytes in the same cuvet in areas such as endocrinology, oncology, infectious disease, and therapeutic drug monitoring. Systems that rely on the differential assay of labels in a liquid mixture or on radionucides are not likely to quantify more than two or three analytes at a time. There are no practical radionucide-label combinations for such assays and, for liquid-based chemistry tests, no more than three lanthanides could form fluorescent complexes that could be individually quantified in each other's presence. Use of conventional fluorophores, which have broad emission spectra, would make simultaneous quantification even more difficult.
One practical approach for true multianalyte immunoassays involves the spatial distribution of immunospots, the responses of which are then quantified with a suitable instrument (14) (15) (16) (17) . The immunospots could carry a detectable moiety, i.e., an insoluble colored precipitate generated by an enzyme (17) or a fluorescent tag. For highly sensitive assays, the fluorescent europium chelates are the labels of choice (13) . In this study we took advantage of a highly sensitive detection reagent based on streptavidin multiply labeled with the fluorescent europium chelate of BCPDA (18) . This reagent can fluorescently label areas containing biotinylated antibodies; the fluorescent areas can be quantified on the dry solid phase by using laser excitation. Multianalyte immunoassay with high sensitivity can thus be achieved by individually quantifying closely spaced fluorescent areas, each one representing one analyte.
Although in theory an unlimited number of analytes can be assayed by such principles (14-16), several practical problems must be considered. For these assays to errors (if the interferent also cross-reacts with the detection antibody). This problem is more pronounced in comparison with singleanalyte assays because more than one detection antibody is present in the reaction mixture. In multianalyte immunoassay designs, it is more difficult to optimize the assay range for all analytes because of the fixed sample volume that must be used. Thus, a larger sample volume can improve the detection limit of one analyte but restrict the dynamic range of another analyte that is present in serum at higher concentrations. The fixed sample volume may also affect assay specificity in some cases.
In conclusion, we present a practical method for multianalyte immunoassay that is sensitive, precise, and accurate
and that gives results comparable with those obtained in individual assays. We believe that this principle warrants further investigation and may prove to be a practical way to simultaneously assay different analytes, especially in areas where panel testing is frequently performed.
